Anti-doping testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
telomeric silencing The repression of transcription of genes in regions adjacent to telomeres. Telomeres also appear to reduce the accessibility of subtelomeric chromatin to modification by DNA methyltransferases.
Initially, Zverev had difficulty adjusting to this training style on the court, saying, "I had no idea what was going on in my body", and needed to adapt his shot technique as he became more muscular. Eventually, he improved on the court. Green remarked, "He started to become less wobbly. He started to absorb the power, so when someone hit hard he could hit the ball back and everything locked into place."
=== Disorders of plasma protein metabolism === 273 Disorders of plasma protein metabolism 273.0 Polyclonal hypergammaglobulinemia 273.1 Monoclonal paraproteinemia 273.2 Other paraproteinemias 273.3 Macroglobulinemia Waldenström macroglobulinemia 273.8 Other disorders of plasma protein metabolism Atransferrinemia
Sources: en.wikipedia.org
== Alternate 5-oxo-ETE producing pathways == The immediate metabolic precursor to 5(S)-HETE, 5(S)-hydroperoxy-6S,8Z,11Z,14Z-eicosatetraenoic acid 5(S)-HpETE, can be converted to 5-oxo-ETE in a non-enzymatic dehydration reaction or chemical lipid peroxidation reactions. The physiological occurrence and relevancy of these reaction pathways has not been ascertained.
Any weapons-grade nuclear material must have a critical mass that is small enough to justify its use in a weapon. The critical mass for any material is the smallest amount needed for a sustained nuclear chain reaction. Moreover, different isotopes have different critical masses, and the critical mass for many radioactive isotopes is infinite, because the mode of decay of one atom cannot induce similar decay of more than one neighboring atom. For example, the critical mass of uranium-238 is infinite, while the critical masses of uranium-233 and uranium-235 are finite. The critical mass for any isotope is influenced by any impurities and the physical shape of the material. The shape with minimal critical mass and the smallest physical dimensions is a sphere. Bare-sphere critical masses at normal density of some actinides are listed in the accompanying table. Most information on bare sphere masses is classified, but some documents have been declassified.
Computing the total disintegration energy given by the equation Edi = (mi - mf - mp)c2 where mi is the initial mass of the nucleus, mf is the mass of the nucleus after particle emission, and mp is the mass of the emitted (alpha-)particle, one finds that in certain cases it is positive and so alpha particle emission is possible, whereas other decay modes would require energy to be added. For example, performing the calculation for uranium-232 shows that alpha particle emission releases 5.4 MeV of energy, while a single proton emission would require 6.1 MeV. Most of the disintegration energy becomes the kinetic energy of the alpha particle, although to fulfill conservation of momentum, part of the energy goes to the recoil of the nucleus itself (see atomic recoil). However, since the mass numbers of most alpha-emitting radioisotopes exceed 210, far greater than the mass number of the alpha particle (4), the fraction of the energy going to the recoil of the nucleus is generally quite small, less than 2%. Nevertheless, the recoil energy (on the scale of keV) is still much larger than the strength of chemical bonds (on the scale of eV), so the daughter nuclide will break away from the chemical environment the parent was in. The energies and ratios of the alpha particles can be used to identify the radioactive parent via alpha spectrometry. These disintegration energies, however, are substantially smaller than the repulsive potential barrier created by the interplay between the strong nuclear and the electromagnetic force, which prevents the alpha particle from escaping.
Sources: en.wikipedia.org
In yeast, acetaldehyde is reduced to ethanol to regenerate NAD+. There are two important anaerobic microbial methane formation pathways, through carbon dioxide / bicarbonate (HCO−3) reduction (respiration) or acetate fermentation.
A member of the People's Assembly (Arabic: عضو مجلس الشعب) refers to members of the Parliament of Syria. Historically, members of the Syrian parliament have been referred to in Arabic as nā'ib (نائب, "deputy"), plural nuwāb (نواب), a usage rooted in the legislature's earlier incarnation as the Chamber of Deputies (1932–1963). Following the parliament's reconstitution as the People's Assembly under Ba'athist rule in 1971, members came to be more commonly styled "member of the People's Assembly" in official and state-media usage. Nonetheless, "deputy" has persisted as a recognised designation, including in coverage of the current transitional-era Assembly formed after 2024.
A higher ratio of body surface area (proportional to heat loss) to body volume (proportional to heat production) A higher proportional surface area of the head A low amount of musculature and the inability to shiver A lack of thermal insulation, e.g., subcutaneous fat and fine body hair (especially in prematurely born children) An inability to move away from cold areas, air currents or heat-draining materials An inability to use additional ways of keeping warm (e.g., drying their skin, putting on clothing, moving into warmer areas, or performing physical exercise) A nervous system that is not fully developed and does not respond quickly and/or properly to cold (e.g., by contracting blood vessels in and just below the skin: vasoconstriction). Heat production in brown fat provides an infant with an alternative means of heat regulation.
Subsequent industry developments have included the involvement of major tobacco companies in the e-cigarette market through subsidiaries and acquisitions; for example, British American Tobacco's U.S. unit Reynolds American markets Vuse products, and in 2023 Altria acquired NJOY's e-vapor product portfolio. In parallel with regulatory scrutiny and industry consolidation, e-cigarette manufacturers have faced significant product liability and consumer protection litigation. In April 2023, Juul Labs agreed to pay $462 million to settle claims brought by six U.S. states and the District of Columbia alleging unlawful marketing of its products to minors. Public safety concerns related to lithium ion batteries have also extended beyond consumer use to storage, disposal, and waste handling. Public safety authorities have warned about fire risks associated with lithium ion batteries in disposable e-cigarettes during storage, disposal and waste handling. Ahead of the United Kingdom's disposable vape ban taking effect in June 2025, the Local Government Association cautioned that lithium batteries inside disposable vapes could pose a fire and risk-to-life hazard if not stored correctly. In the UK, these concerns have been reflected in government and media reporting on waste-related fires. In 2025, reporting linked discarded single use vapes to fires in waste collection vehicles and recycling facilities, citing warning from the Department for Environment, Food & Rural Affairs and estimates of more than 1,200 battery-related fires at waste sites in 2023.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.